Physicochemical and Biological Characterization of Chitosan-microRNA Nanocomplexes for Gene Delivery to MCF-7 Breast Cancer Cells

Overview

Journal Sci Rep

Specialty Science

Date 2015 Sep 2

PMID 26324407

Citations 41

Authors

B Santos-Carballal

L J Aaldering

M Ritzefeld

S Pereira

N Sewald

B M Moerschbacher

M Gotte

F M Goycoolea

Affiliations

Soon will be listed here.

Abstract

Cancer gene therapy requires the design of non-viral vectors that carry genetic material and selectively deliver it with minimal toxicity. Non-viral vectors based on cationic natural polymers can form electrostatic complexes with negatively-charged polynucleotides such as microRNAs (miRNAs). Here we investigated the physicochemical/biophysical properties of chitosan-hsa-miRNA-145 (CS-miRNA) nanocomplexes and the biological responses of MCF-7 breast cancer cells cultured in vitro. Self-assembled CS-miRNA nanocomplexes were produced with a range of (+/-) charge ratios (from 0.6 to 8) using chitosans with various degrees of acetylation and molecular weight. The Z-average particle diameter of the complexes was <200 nm. The surface charge increased with increasing amount of chitosan. We observed that chitosan induces the base-stacking of miRNA in a concentration dependent manner. Surface plasmon resonance spectroscopy shows that complexes formed by low degree of acetylation chitosans are highly stable, regardless of the molecular weight. We found no evidence that these complexes were cytotoxic towards MCF-7 cells. Furthermore, CS-miRNA nanocomplexes with degree of acetylation 12% and 29% were biologically active, showing successful downregulation of target mRNA expression in MCF-7 cells. Our data, therefore, shows that CS-miRNA complexes offer a promising non-viral platform for breast cancer gene therapy.

Citing Articles

Folic Acid-Decorated Chitosan-PLGA Nanobiopolymers for Targeted Drug Delivery to Acute Lymphoblastic Leukemia Cells: Studies.

Ramezani F, Moghadasi M, Shamsasenjan K, Narmani A Technol Cancer Res Treat. 2024; 23:15330338241308077.

PMID: 39711084 PMC: 11672380. DOI: 10.1177/15330338241308077.

Synthesis and study of surface-modified and anti-EGFR DNA aptamer -conjugated chitosan nanoparticles as a potential targeted drug delivery system.

Rahmani Kheyrollahi M, Mohammadnejad J, Eidi A, Jafary H Heliyon. 2024; 10(19):e38904.

PMID: 39435057 PMC: 11491906. DOI: 10.1016/j.heliyon.2024.e38904.

Stimuli-sensitive Chitosan-based Nanosystems-immobilized Nucleic Acids for Gene Therapy in Breast Cancer and Hepatocellular Carcinoma.

Naghib S, Ahmadi B, Mozafari M Curr Top Med Chem. 2024; 24(17):1464-1489.

PMID: 38752630 DOI: 10.2174/0115680266293173240506054439.

Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges.

Rahman M, Afzal O, Najib Ullah S, Alshahrani M, Alkhathami A, Altamimi A ACS Omega. 2024; 8(51):48625-48649.

PMID: 38162753 PMC: 10753706. DOI: 10.1021/acsomega.3c07345.

The important role of miR-1-3p in cancers.

Dai S, Li F, Xu S, Hu J, Gao L J Transl Med. 2023; 21(1):769.

PMID: 37907984 PMC: 10617136. DOI: 10.1186/s12967-023-04649-8.

References

Lee M, Nah J, Kwon Y, Koh J, Ko K, Kim S . Water-soluble and low molecular weight chitosan-based plasmid DNA delivery. Pharm Res. 2001; 18(4):427-31. DOI: 10.1023/a:1011037807261. View

Santos-Carballal B, Swamy M, Moerschbacher B, Goycoolea F . SYBR Gold Fluorescence Quenching is a Sensitive Probe of Chitosan-microRNA Interactions. J Fluoresc. 2015; 26(1):37-42. DOI: 10.1007/s10895-015-1697-8. View

Corsi K, Chellat F, Yahia L, Fernandes J . Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials. 2003; 24(7):1255-64. DOI: 10.1016/s0142-9612(02)00507-0. View

Romoren K, Pedersen S, Smistad G, Evensen O, Thu B . The influence of formulation variables on in vitro transfection efficiency and physicochemical properties of chitosan-based polyplexes. Int J Pharm. 2003; 261(1-2):115-27. DOI: 10.1016/s0378-5173(03)00301-6. View

Lavertu M, Xia Z, Serreqi A, Berrada M, Rodrigues A, Wang D . A validated 1H NMR method for the determination of the degree of deacetylation of chitosan. J Pharm Biomed Anal. 2003; 32(6):1149-58. DOI: 10.1016/s0731-7085(03)00155-9. View

Lundstrom K, Boulikas T . Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat. 2003; 2(5):471-86. DOI: 10.1177/153303460300200513. View

Huang M, Khor E, Lim L . Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res. 2004; 21(2):344-53. DOI: 10.1023/b:pham.0000016249.52831.a5. View

WARSHAW M, Cantor C . Oligonucleotide interactions. IV. Conformational differences between deoxy- and ribodinucleoside phosphates. Biopolymers. 1970; 9(9):1079-103. DOI: 10.1002/bip.1970.360090910. View

Rinaudo M, Milas M, Le Dung P . Characterization of chitosan. Influence of ionic strength and degree of acetylation on chain expansion. Int J Biol Macromol. 1993; 15(5):281-5. DOI: 10.1016/0141-8130(93)90027-j. View

10.

Allan G, Peyron M . Molecular weight manipulation of chitosan. I: Kinetics of depolymerization by nitrous acid. Carbohydr Res. 1995; 277(2):257-72. DOI: 10.1016/0008-6215(95)00207-a. View

11.

Richardson S, Kolbe H, Duncan R . Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm. 1999; 178(2):231-43. DOI: 10.1016/s0378-5173(98)00378-0. View

12.

Huang M, Fong C, Khor E, Lim L . Transfection efficiency of chitosan vectors: effect of polymer molecular weight and degree of deacetylation. J Control Release. 2005; 106(3):391-406. DOI: 10.1016/j.jconrel.2005.05.004. View

13.

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

14.

Lavertu M, Methot S, Tran-Khanh N, Buschmann M . High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials. 2006; 27(27):4815-24. DOI: 10.1016/j.biomaterials.2006.04.029. View

15.

Howard K, Rahbek U, Liu X, Damgaard C, Glud S, Andersen M . RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther. 2006; 14(4):476-84. DOI: 10.1016/j.ymthe.2006.04.010. View

16.

Liu X, Howard K, Dong M, Andersen M, Rahbek U, Johnsen M . The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials. 2006; 28(6):1280-8. DOI: 10.1016/j.biomaterials.2006.11.004. View

17.

Gary D, Puri N, Won Y . Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release. 2007; 121(1-2):64-73. DOI: 10.1016/j.jconrel.2007.05.021. View

18.

Weecharangsan W, Opanasopit P, Ngawhirunpat T, Apirakaramwong A, Rojanarata T, Ruktanonchai U . Evaluation of chitosan salts as non-viral gene vectors in CHO-K1 cells. Int J Pharm. 2007; 348(1-2):161-8. DOI: 10.1016/j.ijpharm.2007.07.011. View

19.

Ma P, Lavertu M, Winnik F, Buschmann M . New insights into chitosan-DNA interactions using isothermal titration microcalorimetry. Biomacromolecules. 2009; 10(6):1490-9. DOI: 10.1021/bm900097s. View

20.

Ranjbar B, Gill P . Circular dichroism techniques: biomolecular and nanostructural analyses- a review. Chem Biol Drug Des. 2009; 74(2):101-20. DOI: 10.1111/j.1747-0285.2009.00847.x. View